Chinese pharma planning global clinical trials for Alzheimer's drug
Shanghai Green Valley Pharmaceutical's treatment GV-971 for Alzheimer's disease was approved by Chinese regulators last November, and the company has announced plans to launch global clinical trials in 200 clinical centers throughout North America, Eastern Europe, the European Union, Asia Pacific and other locations that will be completed by 2024. PMLive (UK) (1/6)
Read full article now.
Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!